BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
월요일, 9월 14

Cogent Biosciences Inc

COGTNASDAQ
Trade with Public
Trade with Public
$33.41
N/A
가까이에: Sep 14, 5:00 PM EST
$33.41
N/A
시간외: 4:00 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Cogent Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cogent Biosciences (COGT).

Price Target Range — 13 Quarters

Analyst Consensus — 12 Analysts

1S.Buy
8Buy
3Hold
Consensus RatingBuy# Analysts12Avg. Consensus PT$38Upside to Avg. PT+12.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Aug 17, 2026Piper SandlerChristopher RaymondPT RaiseOverweight$52→$55
Aug 12, 2026GuggenheimMichael SchmidtPT RaiseBuy$45→$52
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $55

Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $52 to $55.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Cogent Biosciences, Raises Price Target to $52

Guggenheim analyst Michael Schmidt maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $45 to $52.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $55

HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $52 to $55.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $52

Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $39 to $52.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved